Acrivon Therapeutics, Inc. (ACRV) Share-based Payment Arrangement, Expense USD 2021 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Acrivon Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2021 to 2024.
  • Acrivon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $3.34 M, a 26.4% increase year-over-year.
  • Acrivon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $12.3 M, a 157% increase year-over-year.
  • Acrivon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $11.6 M, a 432% increase from 2022.
  • Acrivon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.19 M, a 340% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $12.3 M $3.34 M +$698 K +26.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $11.6 M $3.06 M +$1.41 M +85.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 $10.2 M $3.23 M +$2.96 M +1109% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $7.25 M $2.69 M +$2.45 M +1053% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-11
Q1 2023 $4.79 M $2.65 M +$2.61 M +6685% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $2.19 M $1.65 M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $267 K +$240 K +889% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $233 K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $39 K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q3 2021 $27 K Jul 1, 2021 Sep 30, 2021 10-Q 2022-12-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.